PROK
Prokidney Corp. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$1.29Close
$1.29 – $3.0852-week range
Nov 9, 2026Next report
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 7 · weaker than 93% of stocks over 12 months
- Far from its high 58% below its 52-week high
- Results soon Nov 9, 2026, in 8 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
58%
1wk
down 8.2%
price change
1mo
down 22.0%
price change
12-month return
down 58%
market up 11% ·
its own down 69%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
up 1075%
year on year
EPS growth
—
latest quarter
Sales growth
down 32%
latest quarter · -30 pts
ROE
—
return on equity
Free cash margin
down 15153%
-$135.3M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Trade setup
ATR%
9.0%
$0.12 a day · 2×ATR $1.06
RS
7 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
1.3×
vs 50-day average
Up/down volume
1.41
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$1.0B as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
Last reported
Aug 10, 2026
Results reaction
Aug 10, 2026-1% vs market2 sessions after results
Financials
- Net -7725%
- Free cash -15153%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $76,000 | $893,000 |
| Operating income | -$27.0M | -$55.1M | -$153.0M | -$151.5M | -$183.7M | -$165.0M |
| Net income | -$26.7M | -$55.1M | -$148.1M | -$35.5M | -$61.2M | -$69.0M |
| Net margin | — | — | — | — | -80508% | -7725% |
| Earnings per share | — | — | -$2.41 | — | — | — |
| Free cash flow | -$30.6M | -$55.5M | -$78.9M | -$124.3M | -$155.9M | -$135.3M |
| Free cash margin | — | — | — | — | -205079% | -15153% |
| Cash | $4.6M | $20.6M | $490.3M | $60.6M | $99.1M | $108.5M |
| Shareholders' equity | $9.9M | $26.9M | -$1.1B | -$1.1B | -$995.0M | -$1.0B |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 10, 2026 | Quarterly ↗ | Jun 30, 2026 | 41d |
| May 15, 2026 | Quarterly ↗ | Mar 31, 2026 | 45d |
| Mar 18, 2026 | Annual ↗ | Dec 31, 2025 | 77d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 17, 2025 | Annual ↗ | Dec 31, 2024 | 76d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 9, 2024 | Quarterly ↗ | Jun 30, 2024 | 40d |
| May 10, 2024 | Quarterly ↗ | Mar 31, 2024 | 40d |
| Mar 22, 2024 | Annual ↗ | Dec 31, 2023 | 82d |
| Nov 14, 2023 | Quarterly ↗ | Sep 30, 2023 | 45d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Material agreement ↗ |
| Aug 10, 2026 | Results ↗ |
| May 29, 2026 | Shareholder vote ↗ |
| May 15, 2026 | Results · Regulation FD · Other events ↗ |
| Mar 18, 2026 | Results ↗ |
| Feb 2, 2026 | Regulation FD · Other events ↗ |
| Jan 12, 2026 | Regulation FD ↗ |
| Nov 10, 2025 | Results ↗ |
| Oct 17, 2025 | Material agreement ↗ |
| Aug 12, 2025 | Results ↗ |
| Jul 15, 2025 | Regulation FD · Other events ↗ |
| Jul 14, 2025 | Material agreement · Agreement ended · Other events ↗ |